After the University of Pennsylvania and the U.S. National Institutes of Health (NIH) separately pressed BioNTech for royalties on its Pfizer-partnered COVID-19 vaccine Comirnaty, the German drugmaker has agreed to pay up to resolve the disputes.

BioNTech will pay the NIH $791.5 million, according to a securities filing (PDF). Of the sum, $750 million stems from claimed royalties on the vaccine from 2020 to 2023, while the remaining $41.5 million accounts for entry into an amended license agreement.

As for Penn, the university will get up to $467 million from BioNTech, the company revealed in a separate filing (PDF). That sum includes $400 million in royalties for 2020 to 2023, plus up to $15 million for a three-year extension of a research alliance and $52 million for an R&D investment fund that will be jointly managed by BioNTech and Penn.